Tiers name what a vendor publishes, not a verdict on any product's purity or quality.
Lab-verifiable COAs: certificates that open on the testing lab's own site (the seal's ring shows what share of them do).
Third-party COAs: certificates attributed to a third-party lab, which may be hosted only on the vendor's site.
Tiers follow the Vendor Score (90+ and 80–89), which is 87% COA evidence; the numeral in each seal is that score.
Affiliate relationships never affect tiers, selection or order. How the Vendor Score works
A synthetic 33-amino-acid analog of glucagon-like peptide-2 (GLP-2); the alanine at position 2 is replaced by glycine, which makes the molecule a poorer substrate for DPP-4 than native GLP-2.
FDA-approved as Gattex (NDA 203441) for short bowel syndrome in patients dependent on parenteral support, centrally authorised in the EU and authorised in the UK as Revestive. Approved for short bowel syndrome only — a GLP-2 analogue's approval says nothing about any other use. Research use only — not medical advice.
Selections stay on this browser. Prices and stock come from the current page; review freshness and COA notes for each offer. Scroll sideways to see every offer.
Select up to four offers to compare side by side. Click a column heading to sort. Click again to reverse. Scroll sideways for more columns.
Tick up to four offers to compare side by side. Use Sort by to reorder. COA counts are each vendor's own library; batch match is not assumed.
Teduglutide · all tracked vendors · all tracked peptide listings, including out-of-stock products. Prices and stock reflect the last check. Non-comparable products do not enter market rankings. Trust scores measure published evidence, not product safety.
No matches. Try another search or reset the filters.
COACertificate of Analysis: a lab report stating a batch's measured identity and purity.Certificate of Analysis: a lab report stating a batch's measured identity and purity. availability: 1 of 1 tracked sources for Teduglutide publish a COA
— 1 with at least one certificate you can open at the testing lab : Modern Research Peptides (276 at the lab) . What a COA proves →
Published dosing for Teduglutide
Source-linked reference figures with the population and study context alongside each amount. Study arms are not a starting dose, titration schedule, or personal treatment plan. Label records refer to the named approved medicine, not vendor products.
FDA-approved label dose
0.05 mg/kg once daily
human · adults and pediatric patients 1 year of age and older with short bowel syndrome who are dependent on parenteral support · FDA label (Gattex) · Route reported: subcutaneous
published per unit of bodyweight — pepmg reports it as published and does not convert it to an absolute amount
Research use only — this reports what an FDA label, a peer-reviewed study or a clinical-trial registry entry published, tied to its species and study context. A trial-registry figure is what a sponsor registered, not a peer-reviewed result. It is not medical advice, not a recommendation to use, and no dose here is generated by pepmg. Any dosing decision is for a qualified professional. Animal-study amounts do not establish a human dose.
All products listed are sold by third-party vendors for laboratory and research use only (RUO). Where an FDA label, a peer-reviewed study or a clinical-trial registry entry has published a dose, pepmg reports it with the source named and the tier labeled (a registry figure is marked trial registry, not peer-reviewed), because that is safer than guessing. It is a report, not medical advice and not a recommendation to use anything. pepmg sells nothing and ships nothing. Listings are price-tracking data, not endorsements.
✓
+ Get the free Weekly Price Index One email a week — where every compound's $/mg moved. No spam.